These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22328092)

  • 21. Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?
    Coimbra S; Reis F; Valente MJ; Rocha S; Catarino C; Rocha-Pereira P; Sameiro-Faria M; Bronze-da-Rocha E; Belo L; Santos-Silva A
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34065648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.
    Noels H; Lehrke M; Vanholder R; Jankowski J
    Nat Rev Nephrol; 2021 Aug; 17(8):528-542. PubMed ID: 33972752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Density Lipoproteins and the Kidney.
    Strazzella A; Ossoli A; Calabresi L
    Cells; 2021 Mar; 10(4):. PubMed ID: 33807271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of High-Density Lipoprotein from Healthy Subjects and Chronic Kidney Disease Patients on the CD14 Expression on Polymorphonuclear Leukocytes.
    Cohen G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker.
    Sorić Hosman I; Kos I; Lamot L
    Front Immunol; 2020; 11():631299. PubMed ID: 33679725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Density Lipoproteins and Serum Amyloid A (SAA).
    Webb NR
    Curr Atheroscler Rep; 2021 Jan; 23(2):7. PubMed ID: 33447953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nomogram Based on Risk Factors for Type 2 Diabetes Mellitus Patients with Coronary Heart Disease.
    Shi R; Wu B; Niu Z; Sun H; Hu F
    Diabetes Metab Syndr Obes; 2020; 13():5025-5036. PubMed ID: 33376372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression?
    Márquez AB; Nazir S; van der Vorst EPC
    Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33260660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease.
    Marsche G; Heine GH; Stadler JT; Holzer M
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32967334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycation of HDL blunts its anti-inflammatory and cholesterol efflux capacities in vitro, but has no effect in poorly controlled type 1 diabetes subjects.
    Gomes Kjerulf D; Wang S; Omer M; Pathak A; Subramanian S; Han CY; Tang C; den Hartigh LJ; Shao B; Chait A
    J Diabetes Complications; 2020 Dec; 34(12):107693. PubMed ID: 32900591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Dysfunction in Uremia 2020.
    Cohen G
    Toxins (Basel); 2020 Jul; 12(7):. PubMed ID: 32635646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-Density Lipoprotein (HDL) Inhibits Serum Amyloid A (SAA)-Induced Vascular and Renal Dysfunctions in Apolipoprotein E-Deficient Mice.
    Cai X; Ahmad G; Hossain F; Liu Y; Wang X; Dennis J; Freedman B; Witting PK
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.
    Rysz J; Gluba-Brzózka A; Rysz-Górzyńska M; Franczyk B
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of lipoprotein-associated phospholipase A2, serum amyloid A, and fibrinogen as diagnostic biomarkers for patients with acute cerebral infarction.
    Tao L; ShiChuan W; DeTai Z; Lihua H
    J Clin Lab Anal; 2020 Mar; 34(3):e23084. PubMed ID: 31713292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cardiovascular phenotype of adult patients with phenylketonuria.
    Azabdaftari A; van der Giet M; Schuchardt M; Hennermann JB; Plöckinger U; Querfeld U
    Orphanet J Rare Dis; 2019 Sep; 14(1):213. PubMed ID: 31492166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling disease risk for amyloid A (AA) amyloidosis in non-human primates using machine learning.
    Leung ET; Raboin MJ; McKelvey J; Graham A; Lewis A; Prongay K; Cohen AM; Vinson A
    Amyloid; 2019 Sep; 26(3):139-147. PubMed ID: 31210531
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of serum amyloid A in atherosclerosis.
    Shridas P; Tannock LR
    Curr Opin Lipidol; 2019 Aug; 30(4):320-325. PubMed ID: 31135596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered proteome of high-density lipoproteins from paediatric acute lymphoblastic leukemia survivors.
    Fournier M; Bonneil E; Garofalo C; Grimard G; Laverdière C; Krajinovic M; Drouin S; Sinnett D; Marcil V; Levy E
    Sci Rep; 2019 Mar; 9(1):4268. PubMed ID: 30862935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysfunctional high-density lipoprotein activates toll-like receptors via serum amyloid A in vascular smooth muscle cells.
    Schuchardt M; Prüfer N; Tu Y; Herrmann J; Hu XP; Chebli S; Dahlke K; Zidek W; van der Giet M; Tölle M
    Sci Rep; 2019 Mar; 9(1):3421. PubMed ID: 30833653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Density Lipoprotein from Chronic Kidney Disease Patients Modulates Polymorphonuclear Leukocytes.
    Raupachova J; Kopecky C; Cohen G
    Toxins (Basel); 2019 Feb; 11(2):. PubMed ID: 30717079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.